KR19990069591A - Sexual Dysfunction Therapeutics and Treatment Methods - Google Patents

Abstract

A therapeutic agent for sexual dysfunction containing an effective amount of milnonone alone or in combination with one or two or more selected from the group consisting of papaverine, chlorpromazine, atropine, yohimbine, and prostaglandin E1. When used in combination with any one or multiple of promazine, atropine, yohimbine and prostaglandin E1, it is highly improved compared to any one or multiple combinations of papaverine, chlorpromazine, atropine, yohimbine and prostaglandin E1 that exclude milinon. Sexual therapeutic effects can be obtained.

Description

Sexual Dysfunction Therapeutics and Treatment Methods

The present invention relates to a method for treating sexual dysfunction, and more particularly, to a method for treating male or female sexual dysfunction by administering an effective amount of milrinone to a male or female.

Most sexual dysfunction is known to occur after the 50's, but surprisingly many men and women in the 30's are contemplating sexual dysfunction. Male sexual dysfunction is erectile dysfunction, premature ejaculation, inability to ejaculate, delayed ejaculation, hypogonadism, and in women, insensitivity.

These sexual dysfunctions cause sexual boredom, and this boredom can cause stress and various physical symptoms and damage to others. For example, even if you work, your efficiency does not go up at all, causing damage to people around you.

Therefore, the present invention is to make it possible to effectively treat the sexual dysfunction causing such a problem as a technical problem.

According to the present invention for solving the above problems there is provided a therapeutic agent for sexual dysfunction containing an effective amount of milrinone.

The present invention also provides a method for treating male or female sexual dysfunction comprising administering an effective amount of milrinone to a male or female.

Hereinafter, the present invention will be described in more detail.

The therapeutic agent for sexual dysfunction of the present invention is Milnone alone, or a second therapeutic ingredient that enhances the action of Milnon, such as an alpha-adrenergic blocker, phosphodiesterase inhibitor , PGE prostaglandin type (prostaglandin type), an atropinic agent (alpha) and one or two or more selected from the group consisting of alpha blocker itself consisting of some alpha 2 together. For example, the therapeutic agent is one selected from the group consisting of papaverine, chlorpromazine, phentolamine, atropine, yohimbine, and prostaglandin E1. Or it may contain two or more kinds and the millon together. Such therapeutic agents of the present invention are very effective in treating sexual dysfunction.

In addition, the present therapeutic agent may contain a pharmaceutically acceptable carrier or diluent commonly used in the manufacture of a medicament, and may also contain a penetration-enhancing agent.

In addition, the therapeutic agent has a significant side reaction effect on prostaglandin E1 and is effective for use in place of prostaglandin E1 in patients with mild response. The administration of the present drug can be applied by intracavernosal injection, topical application or impregnation, transmalmal administration, or intraurethral administration.

Features and other advantages of the present invention as described above will become more apparent from the embodiments described below.

EXAMPLE

Millenone alone or in combination with papainrin, chlorpromazine, pentoramine, atropine, yohimbine and prostaglandin E1, or one or two or more selected from the group consisting of milone It was compared with erectile activity by any combination taken from the group consisting of promazine, pentoramine, atropine, yohimbine and prostaglandin El.

These effects were performed in 176 patients with various pathologies. All patients were classified into five grades, and the same physicians rated and graded the erection system as palpation and screening. 1 degree had no erection, 2 degree had some swelling, 3 degree completely inflated but no stiffness, 4 degree incomplete stiffness and 5 degree full stiffness. Erection time, erection duration and side effects were also recorded. Arterial blood flow was measured as an ultrasonic Doppler and the mean blood flow rate of 20-25 cm / sec was assumed to be the lower limit of normality.

[Analysis]

Milnon sole

After injecting 0.38 mg of Milline into 12 patients, 5 (41%) had no response or a slight erection (1-2 degrees) and 4 (33%) had an erectile erection (3 degrees) and 3 others ( 25%) showed an erection showing 4 to 5 degrees of stiffness. The average time from injection to erection was about 12 minutes and the duration of erection averaged 28 minutes.

Atropine sole

Nine patients were injected with 0.12 mg of atropine but it was ineffective in all of them (1 degree).

Atropine vs. atropine / milnon

11 patients were injected with 0.12 mg of atropine, but it was not effective in all patients (1 degree), but 0.38 mg of myronone and 0.12 mg of atropine were injected into 11 of the same patients. Corresponding erectile erection was observed, and 4 patients (36%) showed 3 degree of non-stiff erection, erection duration was 10 minutes and erection duration was 43 minutes.

Chlorpromazine / Atropine vs. Chlorpromazine / Atropine / Mininon

Eight patients were injected with 3.1 mg of chloropromazine and 0.12 mg of atropine. Five patients (62%) had an erectile stiffness of 4 to 5 degrees and three patients (38%) had no stiffness after injecting 0.38 mg of milnonone, 3.1 mg of chlorpromazine, and 0.12 mg of atropine into eight patients. Simple erection (3 degrees) appeared, the average erection expression time was 11 minutes and the average erection duration was 39 minutes.

Pentoramine / Atropine vs Pentoramine / Atropine / Mininon

Nine patients received 2 mg of pentoramine and 0.2 mg of atropine. All 9 patients were ineffective (1 degree).

Injecting 0.38 mg of Millon, 2 mg of pentoramine, and 0.2 mg of atropine into the same 9 patients resulted in 4-5 degrees of erectile erection in 6 patients (67%) and 3 degrees of stiffness in 3 patients (33%). Simple erection was shown, and erection expression time averaged 8 minutes and average erection duration of 58 minutes.

Papaverine / Chlorpromazine / Atropine vs Papaverine / Chlorpromazine / Atropine / Mininon

Papaverine 11.25 mg, chlorpromazine 3.1 mg, and atropine 0.12 mg were injected into 13 patients, resulting in 4 to 5 degrees of erectile erection in 7 patients (54%) and the remaining 6 patients (46%) Brought. Erectile expression time averaged 9 minutes and lasted 78 minutes.

Millinen 0.38 mg, papaverine 11.25 mg, chlorpromazine 3.1 mg, and atropine 0.12 mg were injected into the same 13 patients, which showed 4-5 degrees in 11 patients (84%). Was too. Erectile expression averaged 9 minutes and lasted 96 minutes.

Papaverine / Pentoramine / Atropine vs Papaverine / Pentoramine / Atropine / Milnon

In 14 patients, papaverine 11.25 mg, pentoramine 2 mg, and atropine 0.2 mg were injected into 4 to 5 degrees in 8 patients (57%), and the remaining 6 (43%) were 3 degrees. The erection expression was 8 minutes and the erection lasted 98 minutes.

Injecting 0.38 mg of quinone, 11.25 mg of papaverine, 2 mg of pentoramine, and 0.2 mg of atropine into the same 14 patients showed stiffness of 4-5 degrees in 12 patients (85%) and the remaining 2 patients (15%). 3 degrees. Erectile expression appeared at 7 minutes and lasted 126 minutes.

Papaverine / Chlorpromazine / Atropine / Yohimbine vs Papaverine / Chlorpromazine / Atropine / Yohimbine / Milon

Papaverine 15 mg, chlorpromazine 5 mg, atropine 0.15 mg, and yohimbine 1.75 mg were injected into 50 patients with an erection of 4-5 degrees in 35 (70%) and 3 degrees (30 in 15 (30%)). %) Erection appeared. The erection expression was 9 minutes and the erection duration was 86 minutes.

Millinen 0.38 mg, papaverine 15 mg, chlorpromazine 5 mg, atropine 0.15 mg, and yohimbine 1.75 mg were injected into the same 50 patients with 4-5 degrees in 48 patients (96%) and the remaining 2 patients (4%). ), 3 degrees. Erectile expression was 9 minutes and an erection duration of 138 minutes.

Papaverine / Panthoramin / Atropine / Yohimbine vs Papaverine / Pentoramin / Atropine / Yohimbine / Mininon

Papaverine 15 mg, pentoramine 2 mg, atropine 0.15 mg, and yohimbine 1.75 mg were injected into one patient, resulting in erection of 4-5 degrees in 13 patients (72%) and 3 degrees in the remaining 5 patients (28%). Indicated. It took 10 minutes of erection expression and lasted 73 minutes of erection.

Mildon 0.38 mg, papaverine 15 mg, pentoramine 2 mg, atropine 0.15 mg, and yohimbine 1.75 mg were administered to the same 18 patients, and the erectile ability of 4-5 degrees to 17 patients (94%) was one (6%). Showed three degrees of stiffness. An erection expression time of 8 minutes and an erection duration of 124 minutes were shown.

Papaverine / Chlorpromazine / Atropine / Prostaglandin E1 vs Papaverine / Chlorpromazine / Atropine / Prostaglandin E1 / Mininon

Papaverine 11.25 mg, chlorpromazine 3.1 mg, atropine 0.12 mg, and prostaglandin E1 5 mg were administered to 9 patients, resulting in an anorexic erectile of 4 to 5 degrees in 6 patients (67%) and the remaining 3 patients (33%). 3 degrees. An erection time of 10 minutes was measured and an erection lasted 92 minutes.

As a result of adding 0.38mg of Millionone to the same drug and the amount, the same patient was administered to 9 patients, and 8 (89%) showed 4 ~ 5 degrees of erection, and the remaining 1 (11%) had 3 degrees of erection. Seemed. An erection time of 9 minutes was required and an erection lasted 134 minutes.

Papaverine / pentoramine / atropine / prostaglandin E1 vs papaverine / pentoramine / atropine / prostaglandin E1 / milnon

Papaverine 18 mg, pentoramine 2 mg, atropine 0.2 mg, and prostaglandin E1 5 mg were administered to 14 patients with 4 to 5 degrees of stiffness in 10 patients (71%) and 3 degrees in the other 4 (29%). Indicated. Erectile expression was 11 minutes and mean erection duration was 82 minutes.

As a result of adding 0.38 mg of Millionone to the same drug and amount as described above, 14 patients were treated with the same drug. As a result, 13 (82%) patients had 4 to 5 degrees of erection, and the remaining 1 (8%) had 3 degrees of erection. 9 minutes of erection expression time and 143 minutes of erection duration were shown.

Papaverine / pentoramine / atropine / yohimbine / prostaglandin E1 vs papaverine / pentoramine / atropine / yohimbine / prostaglandin E1 / millionone

Papaverine 18 mg, pentoramine 2 mg, atropine 0.2 mg, yohimbine 1.75 mg and prostaglandin E1 5 mg were injected in 11 patients with 4-5 degrees in 8 (73%) and 3 in the remaining 3 (27%). The erection power of the figure is shown.

As a result of injecting 0.38 mg of Millionone into the same drug and amount as described above, the same patient was injected into 11 patients, and erectile power of 4 degrees in 10 patients (91%) and 3 degrees in 1 patient (9%) was observed. An erection expression time of 8 minutes and an erection duration of 132 minutes were shown.

Clit Application Effect of Milon Gel Combined with Papaverine / Chlorpromazine / Pentoramin / Atropine / Yohimbine in Sensitized Women

Ultrasound doppler of the clitoris was tested in eight normal sexually active support women with primary insensitivity. Significant changes in Doppler parameters were found before and after clitoris application of the Milnon gel. The results obtained in this experiment are based on the results obtained by injecting a milnonone gel containing papaverine, glorpromazine, pentoramine, atropine, and yohimbine into male corpus cavernosum, and the response of blood vessels around the clitoris in women. It was found that the reaction was almost similar. After application of the milinon gel to the clitoris, all eight female patients in sexual arousal were able to feel complete orgasm during sexual intercourse or by stimulation of the sexual partner.

As can be seen from the experiments of the above examples, milnonone alone has a much lower erection than any combination of papaverine, chlorpromazine, atropine, yohimbine and prostaglandin E1 in terms of erection intensity and duration. Although active, it has been demonstrated that milinon, when combined with papaverine, chlorpromazine, atropine, yohimbine, and prostaglandin E1 in patients, triggers the erections that patients have experienced in normal sexual activity. From this fact, it can be seen that Milon provides a strong synergistic effect. Together with papaverine, even stronger than papaverine, milinon acts at the post-receptor level through inhibition of phosphodiesterase (the obvious increase in cyclic adenosine monophosphate is calcium Attenuating α1 receptor-mediated contraction of smooth muscle cells by inhibiting ionmobilisation). Moreover, the alpha containment properties of yohimbine appear to be at least as effective as pentoramine, while prostrandine E1 acts through the membrane-receptor. Atropine acts to elevate the action of other active products on pathological erectile tissues by interfering with mechanisms that trigger smooth muscle relaxation.

That is, when used in combination with any one or multiple of papaverine, chlorpromazine, atropine, yohimbine, and prostaglandin E1, milinon is used in any of papainerin, chlorpromazine, atropine, yohimbine, and prostaglandin E1 excluding It was confirmed that the synergistic effect of Milon was very large since it was very effective compared to one or many combinations.

Claims (7)

A therapeutic agent for sexual dysfunction, which contains an effective amount of milnonone. The method of claim 1, wherein the alpha-adrenergic blocker, phosphodiesterase inhibitor, PGE prostaglandin type, atropinic agent, some alpha A therapeutic agent for sexual dysfunction, characterized in that it contains together one or two or more selected from the group consisting of alpha blocker itself consisting of 1 and some alpha 2 and milnonone. The therapeutic agent for sexual dysfunction according to claim 1 or 2, which contains a pharmaceutically acceptable carrier or diluent. The therapeutic agent for sexual dysfunction according to claim 1 or 2, further comprising a penetration-enhancing agent. A method of treating sexual dysfunction comprising administering to a man or woman a therapeutic agent containing an effective amount of milnonone. 6. The therapeutic agent of claim 5, wherein the therapeutic agent is an alpha-adrenergic blocker, a phosphodiesterase inhibitor, a PGE prostaglandin type, an atropinic agent. , Partial alpha 1 and some alpha 2 alpha blocker itself consisting of one or two selected from the group consisting of a method and treatment of sexual dysfunction, characterized in that it contains together. The method for treating sexual dysfunction according to claim 5 or 6, wherein the method of administration is intracavernosal injection, topical application or impregnation, transdermal administration, or intraurethral administration.